Salah-Eddin Al-Batran
Heidelberg University
293 Papers
2.3K Citations
Salah-Eddin Al-Batran is an academic researcher from Heidelberg University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 45, co-authored 238 publications.
Chat about Author
Papers
Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.
Ugur Sahin,Özlem Türeci,Georgy M. Manikhas,Florian Lordick,Andriy Rusyn,Ihor Vynnychenko,Assen Dudov,Igor Bazin,Igor Bondarenko,Bohuslav Melichar,Karl Dhaene,Kai Wiechen,Daniel Maurus,Martin Schuler,Salah-Eddin Al-Batran +14 more
TL;DR: Addition of zolbetuximab to first-line chemotherapy resulted in significantly longer PFS and OS and higher ORR with manageable toxicity and most AEs considered related to zol Betoximab and EOX were of grade ≤ 2 severity; there was no significant increase in grade ≥ 3 events.
22
Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.
Martin Schuler,Zanete Zvirbule,Florian Lordick,Anna Krilova,Ulrike Helbig,Henning Schulze-Bergkamen,Peter C. Thuss-Patience,Goetz von Wichert,Karsten Schulmann,Tanja Trarbach,Stefan Bauer,Christian Mueller,Salah-Eddin Al-Batran,Christoph Huber,Ugur Sahin,Ö. Türeci +15 more
TL;DR: IMAB362 is a monoclonal antibody targeting isoform 2 of the tight junction component claudin 18 (CLDN18.2), a tumor-selective antigen frequently expressed in several types of epith...
21
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Yelena Y Janjigian,Salah-Eddin Al-Batran,O. Wainberg,K. Muro,D. Molena,Eric Van Cutsem,Woo Jin Hyung,Lucjan Wyrwicz,D. Oh,T. Omori,Markus Moehler,Marcelo Garrido,S. C. Oliveira,Moishe Liberman,Victor Castro Oliden,Elizabeth C Smyth,Alexander Stein,M. Bilici,Maria Lorena Alvarenga,Vadim Kozlov,Fernando Rivera,Akihito Kawazoe,Olivier Serrano,E. Heilbron,Alejandra Negro,J. Kurland,J. Tabernero +26 more
21
Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.
Claudia Pauligk,Andrea Tannapfel,Johannes Meiler,Kim Barbara Luley,Hans-Georg Kopp,Nils Homann,Ralf Hofheinz,Harald Schmalenberg,Stephan Probst,Georg Martin Haag,Matthias Egger,Dirk Behringer,Jan Stoehlmacher,Nicole Prasnikar,Andreas Block,Jörg Trojan,Michael Koenigsmann,Wolff Schmiegel,Elke Jäger,Salah-Eddin Al-Batran +19 more
TL;DR: Data from the phase II/III study comparing perioperative FLOT with ECF(X) in resectable stages were analyzed for pathological response upon request of the German Cancer Aid in order to further sponsor the trial.
21
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Melanie Kripp,Salah-Eddin Al-Batran,Johanna Rosowski,Claudia Pauligk,Nils Homann,Jörg T. Hartmann,Markus Moehler,Ralf-Dieter Hofheinz +7 more
TL;DR: Elderly patients in need of intensified chemotherapy may receive FLOT without compromising patient-reported outcome parameters, and no negative impact of the addition of docetaxel on QOL parameters could be demonstrated.